Clinical Trials Logo
  1. Home
  2. Neuroblastoma Recurrent
  3. NCT02139397

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Neuroblastoma Recurrent Clinical Trial

Official title:
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma

Clinical Trial Summary

The purpose of this research study is to evaluate an investigational drug (DFMO) in combination with bortezomib, for relapsed and refractory neuroblastoma. DFMO is an investigational drug because it has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the safety and tolerability of DFMO in combination with bortezomib as well as the tumors response to this study drug.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02139397
Study type Interventional
Source Milton S. Hershey Medical Center
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 6, 2014
Completion date January 19, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03242603 - Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells Phase 1/Phase 2
Terminated NCT04560166 - Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma Phase 2
Recruiting NCT04903899 - 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma Phase 2
Recruiting NCT04239092 - 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1
Not yet recruiting NCT06465199 - Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas Phase 1/Phase 2
Recruiting NCT03373097 - Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Phase 1/Phase 2
Recruiting NCT05754684 - Quadruple Immunotherapy for Neuroblastoma Phase 2
Completed NCT01467986 - Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma Phase 2
Completed NCT02258815 - CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma Phase 2